Therapeutic Potential of Cucurbitacin I in Colon Adenocarcinoma Is Mediated by Modulation of SDHA Expression
Journal of Cellular and Molecular Medicine · 2026-06 · 30 (11)
DOI: 10.1111/jcmm.71231 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 09.06.2026. Verfasst von Danni Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Intelligent Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China. Hauptthemen laut MEDLINE: Adenocarcinoma, Colonic Neoplasms, Gene Expression Regulation, Neoplastic, Triterpenes. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Sichuan Provience.
Abstract (Originalsprache)
Colorectal cancer is a prevalent malignancy, with colon adenocarcinoma (COAD) representing its most common histological subtype. Although most stage I patients remain disease‐free after treatment, a subset rapidly progresses to advanced disease with markedly reduced survival. Therefore, identifying early molecular warning signals in stage I patients is essential for timely intervention. In this study, integrated datasets from The Cancer Genome Atlas and Genotype‐Tissue Expression projects were analysed using the landscape dynamic network biomarker ( l ‐DNB) approach to identify progression biomarkers (PBs) for COAD. Twenty PBs were identified, among which succinate dehydrogenase complex flavoprotein subunit A (SDHA) was selected for further investigation. The L1000CDS 2 database was subsequently queried utilizing these identified PBs, identifying Cucurbitacin I (CuI) as a promising therapeutic component against COAD. Molecular docking and molecular dynamics simulations demonstrated stable binding between CuI and SDHA, with a binding energy of −9.44 kcal/mol and an RMSD of 2.0 ± 0.3 Å. Subsequent in vitro experiments demonstrated that CuI treatment upregulated SDHA expression and inhibited activation of the NF‐κB pathway. Collectively, these findings suggest that the identified PBs may serve as early‐warning indicators for stage I COAD patients and that CuI suppresses COAD cell proliferation, potentially through the SDHA/NF‐κB axis, highlighting its promise as a potential therapeutic candidate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Intelligent Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- Institute of Herbgenomics, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Förderung
- Natural Science Foundation of Sichuan Provience
Zitieren
APA
Zhao, D., Zhang, X., Xiao, W., Lin, Y., Wu, Z., Tang, X., Cheng, Q., Feng, P., & Chen, W. (2026). Therapeutic Potential of Cucurbitacin I in Colon Adenocarcinoma Is Mediated by Modulation of SDHA Expression. Journal of Cellular and Molecular Medicine, 30(11). https://doi.org/10.1111/jcmm.71231
Vancouver
Zhao D, Zhang X, Xiao W, Lin Y, Wu Z, Tang X, et al. Therapeutic Potential of Cucurbitacin I in Colon Adenocarcinoma Is Mediated by Modulation of SDHA Expression. Journal of Cellular and Molecular Medicine. 2026;30(11). doi:10.1111/jcmm.71231
BibTeX
@article{Zhao2026,
author = {Zhao, Danni and Zhang, Xunzhi and Xiao, Wenke and Lin, Yue and Wu, Zhixiang and Tang, Xinyu and Cheng, Qian and Feng, Pengmian and Chen, Wei},
title = {Therapeutic Potential of Cucurbitacin I in Colon Adenocarcinoma Is Mediated by Modulation of SDHA Expression},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
volume = {30},
number = {11},
doi = {10.1111/jcmm.71231}
}
EUVIMED